R Sposto

Summary

Publications

  1. ncbi request reprint A strategic view of randomized trial design in low-incidence paediatric cancer
    R Sposto
    Children s Cancer Group, University of Southern California School of Medicine, Arcadia 91066 6012, USA
    Stat Med 18:1183-97. 1999
  2. ncbi request reprint Cure model analysis in cancer: an application to data from the Children's Cancer Group
    Richard Sposto
    Children s Oncology Group and USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Stat Med 21:293-312. 2002
  3. ncbi request reprint Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group
    R Sposto
    Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Med Pediatr Oncol 37:432-41. 2001
  4. pmc Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
    W Cai
    Division of Hematology Oncology, MS 119, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Br J Cancer 103:1369-79. 2010
  5. ncbi request reprint Palpable breast cancers are inherently different from nonpalpable breast cancers
    K A Skinner
    Department of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine, The University of Southern California, Los Angeles 90033, USA
    Ann Surg Oncol 8:705-10. 2001
  6. ncbi request reprint Breast cancer after augmentation mammoplasty
    K A Skinner
    Department of Surgery, Kenneth Norris, Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles 90033, USA
    Ann Surg Oncol 8:138-44. 2001
  7. ncbi request reprint Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma
    Roger J Packer
    Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
    J Clin Oncol 24:4202-8. 2006
  8. pmc Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
    Mitchell S Cairo
    Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Blood 109:2736-43. 2007
  9. ncbi request reprint Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    Cameron K Tebbi
    Children s Oncology Group, Statistics and Data Center, Arcadia, CA, USA
    J Clin Oncol 25:493-500. 2007
  10. ncbi request reprint Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group
    Richard Sposto
    Children s Center for Cancer and Blood Diseases, Children s Hospital Los Angeles, Los Angeles, CA 90027 6016, USA
    J Clin Oncol 25:2070-7. 2007

Collaborators

Detail Information

Publications30

  1. ncbi request reprint A strategic view of randomized trial design in low-incidence paediatric cancer
    R Sposto
    Children s Cancer Group, University of Southern California School of Medicine, Arcadia 91066 6012, USA
    Stat Med 18:1183-97. 1999
    ..From this viewpoint, insistence on large trials and stringent evidence for accepting new treatments can be counter-productive, in that likely gains in efficacy of treatment will be smaller over the long term...
  2. ncbi request reprint Cure model analysis in cancer: an application to data from the Children's Cancer Group
    Richard Sposto
    Children s Oncology Group and USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Stat Med 21:293-312. 2002
    ..Despite their reliance on explicit parametric forms, PCMs often provide a good description of cancer outcome, and are insensitive to lack of fit provided that follow-up is sufficient...
  3. ncbi request reprint Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group
    R Sposto
    Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Med Pediatr Oncol 37:432-41. 2001
    ..Therefore, in 1983 CCG initiated study CCG-503, a randomized trial of COMP vs. daunomycin-COMP (D-COMP) in children and adolescents with disseminated NLB NHL...
  4. pmc Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
    W Cai
    Division of Hematology Oncology, MS 119, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Br J Cancer 103:1369-79. 2010
    ..Using neuroblastoma pre-clinical models, we determined whether the inhibition of MGMT by O(6)-benzylguanine (O6-BG) could enhance the anti-tumour activity of TMZ and irinotecan...
  5. ncbi request reprint Palpable breast cancers are inherently different from nonpalpable breast cancers
    K A Skinner
    Department of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine, The University of Southern California, Los Angeles 90033, USA
    Ann Surg Oncol 8:705-10. 2001
    ..We examined the clinicopathologic profile of T1 cancers to determine whether palpable cancers are different from nonpalpable cancers...
  6. ncbi request reprint Breast cancer after augmentation mammoplasty
    K A Skinner
    Department of Surgery, Kenneth Norris, Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles 90033, USA
    Ann Surg Oncol 8:138-44. 2001
    ..It is thought that implants interfere with breast cancer diagnosis and that cancers in women who have had breast augmentation carry a worse prognosis...
  7. ncbi request reprint Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma
    Roger J Packer
    Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
    J Clin Oncol 24:4202-8. 2006
    ..To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies...
  8. pmc Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
    Mitchell S Cairo
    Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Blood 109:2736-43. 2007
    ..001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement)...
  9. ncbi request reprint Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    Cameron K Tebbi
    Children s Oncology Group, Statistics and Data Center, Arcadia, CA, USA
    J Clin Oncol 25:493-500. 2007
    ..We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs)...
  10. ncbi request reprint Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group
    Richard Sposto
    Children s Center for Cancer and Blood Diseases, Children s Hospital Los Angeles, Los Angeles, CA 90027 6016, USA
    J Clin Oncol 25:2070-7. 2007
    ....
  11. ncbi request reprint The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group
    Lisa A Teot
    Children s Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Pediatr Dev Pathol 10:199-207. 2007
    ..This article examines the historical usage and current status of the central pathology review process and the rationale and indications for its performance...
  12. ncbi request reprint Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors
    Stergios Zacharoulis
    Department of Pediatrics, The Royal Marsden Hospital, Sutton, Surrey, UK
    Pediatr Blood Cancer 50:231-5. 2008
    ..Metastatic ependymoma is exceedingly rare at diagnosis with variable prognosis reported in the literature. The purpose of this study was to identify prognostic factors in children with metastatic ependymoma...
  13. ncbi request reprint Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report
    Rodney R Miles
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, USA
    Br J Haematol 138:506-12. 2007
    ..These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL...
  14. ncbi request reprint Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and I
    Jason Fangusaro
    Children s Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:312-8. 2008
    ....
  15. doi request reprint Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols
    Girish Dhall
    Childrens Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:1169-75. 2008
    ..To determine the survival of infants and young children with non-metastatic medulloblastoma using intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)...
  16. doi request reprint Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
    Mary Gerrard
    Sheffield Children s Hospital, Sheffield, UK
    Br J Haematol 141:840-7. 2008
    ..5 months, the 4 year event-free survival is 98.3% and overall survival is 99.2%. Children with resected localized B-NHL can be cured with minimal toxicity following two courses of low intensity treatment without IT chemotherapy...
  17. ncbi request reprint Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue
    Stergios Zacharoulis
    Department of Pediatric Hematology Oncology, Children s Hospital Los Angdes, Neural Tumors Program, Los Angles, CA 900 27, USA
    Pediatr Blood Cancer 49:34-40. 2007
    ....
  18. ncbi request reprint Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933
    Tobey J Macdonald
    Department of Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
    Cancer 104:2862-71. 2005
    ..High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors. The role of high-dose chemotherapy (HDCT) in the treatment of HGA remains unclear...
  19. ncbi request reprint Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08
    Mark A Lones
    Pathology Department, Children s Hospital of Orange County St Joseph Hospital, Orange, California, USA
    J Pediatr Hematol Oncol 26:169-78. 2004
    ..Burkitt-like lymphomas were not associated with CMYC translocations. Further studies are warranted in larger cohorts of children and adolescents with Burkitt and Burkitt-like lymphomas...
  20. ncbi request reprint Expression of p53 and prognosis in children with malignant gliomas
    Ian F Pollack
    Department of Neurosurgery, University of Pittsburgh Medical Center and Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    N Engl J Med 346:420-7. 2002
    ..We investigated whether mutations in the TP53 gene or the degree of expression of p53 protein in high-grade gliomas is associated with progression-free survival in children with these tumors...
  21. ncbi request reprint Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report
    Mark A Lones
    Pathology Department, Children s Hospital of Orange County St Joseph Hospital, Orange, CA, USA
    J Clin Oncol 20:2293-301. 2002
    ..NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents...
  22. ncbi request reprint Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort
    Ian F Pollack
    Departments of Neurosurgery, University of Pittsburgh Medical Center and the Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Neurosurgery 50:1238-44; discussion 1244-5. 2002
    ....
  23. ncbi request reprint Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group
    Mark T Jennings
    Vanderbilt Cancer Center, Nashville, TN, USA
    J Clin Oncol 20:3431-7. 2002
    ..This Children's Cancer Group group-wide phase II trial evaluated the efficacy and toxicity of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy (HFEBRT)...
  24. ncbi request reprint Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy
    James B Nachman
    Section of Pediatric Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 20:3765-71. 2002
    ....
  25. ncbi request reprint Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer
    Carol S Woo
    Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Am J Surg 184:337-40. 2002
    ..The purpose of the current study was to determine whether the presence or absence of peritumoral lymphovascular invasion (LVI) contribute further significant information in assessing survival...
  26. ncbi request reprint Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, New York, USA
    Am J Hematol 72:53-63. 2003
    ..Large numbers of patients treated with shorter and intense therapy are required to confirm these preliminary observations...
  27. ncbi request reprint Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers
    Vani Sabesan
    Indiana University School of Medicine, Indianapolis, USA
    J Pediatr Hematol Oncol 25:109-13. 2003
    ..This study demonstrated the feasibility of PSPs to identify disease in staging and follow-up specimens, which could be used to develop strategies for MRD analysis in a larger setting...
  28. ncbi request reprint Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital New York, Columbia University, New York, NY, USA
    Br J Haematol 120:660-70. 2003
    ..001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy...
  29. ncbi request reprint Breast cancer: do specialists make a difference?
    Kristin A Skinner
    Department of Surgery, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Ann Surg Oncol 10:606-15. 2003
    ..Many believe that breast cancer should be treated by specialists. We studied the effect of surgeon and hospital specialization on survival after breast cancer treatment in a large, well-defined patient population...
  30. ncbi request reprint High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors
    Alberto Broniscer
    Children s Cancer Group New York University Medical Center, New York, NY, USA
    Pediatr Blood Cancer 42:261-7. 2004
    ..XSWe tested the efficacy of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in this setting...